-
Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects
Friday, November 25, 2016 - 11:12am | 353Read More...H.C. Wainwright said it is not surprised by Eli Lilly and Co (NYSE: LLY)’s announcement of solanezumab failing to slow the cognitive decline in Alzheimer’s Disease patients. The news is also said to be a negative for Biogen Inc (NASDAQ: BIIB), which is testing its own Alzheimer's...
-
Vertex Pharmaceuticals Relapses To A Neutral Rating At H.C. Wainwright
Monday, October 24, 2016 - 9:06am | 382Read More...H.C. Wainwright & Co. downgraded shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) from Buy to a Neutral rating citing that fundamentals are not holding up. The firm also slashed its target price from $155 to $85 on the stock implying about 5 percent upside potentials from the...
-
TG Therapeutics Pulling Off The Band-Aid To Keep GENUINE Cancer Study On Track
Friday, October 14, 2016 - 11:11am | 390Read More...H.C. Wainwright maintains Buy rating on TG Therapeutics Inc (NASDAQ: TGTX) as it welcomes the company’s amendment of a cancer study called GENUINE. Under GENUINE, TG is studying Ublituximab in combination with Ibrutinib versus Ibrutinib alone in patients with previously treated high-risk...
-
'Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality,' H.C. Wainwright Says
Monday, August 22, 2016 - 9:28am | 360Read More...H.C.Wainwright & Co. initiated coverage on Kadmon Holdings Inc (NYSE: KDMN) with a Buy rating and a price tag of $25, citing varied clinical pipeline. Analysts led by Andrew Fein categorized biotech firms into three sections. The first category belonged to those that have proven track record,...
-
H.C. Wainwright Downgrades United Therapeutics To Neutral
Wednesday, June 15, 2016 - 12:04pm | 315Read More...H.C. Wainwright & Co. analysts Andrew Fein and Emile Yu have downgraded the shares of United Therapeutics Corporation (NASDAQ: UTHR) to a Neutral rating, pointing out that the scales are tipping the other way. The brokerage also lowered its price objective to $95. "We see no short-term drivers...
-
H.C. Wainwright Triples Celator Valuation, Says Latest Trial Win Is Rare
Tuesday, March 15, 2016 - 10:40am | 259Read More...On Tuesday, H.C. Wainwright & Co. issued a company note on Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) after the company had a positive Phase 3 trial win in oncology, with a survival win in AML of their drug Vyxeos. After the news, analysts at H.C. Wainwright reiterated their Buy rating...
-
Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside
Monday, July 6, 2015 - 8:34am | 290Read More...In a report published Monday, H.C. Wainwright analyst Andrew S. Fein maintained a Neutral rating and $85 price target on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). The analyst believes that the Orkambi launch is "hyped." "Last week, just 5 months after POTUS indirectly praised VRTX at the...
-
Threshold Pharmaceuticals, Inc. Shares Jump Amid H.C. Wainwright Initiation
Friday, September 5, 2014 - 9:43am | 161Read More...In a note released Friday morning, H.C. Wainwright analyst Andrew Fein initiated coverage of Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) with a Buy rating and a $12 price target. Fein's optimistic view for the stock is based on the company's "value driver" TH-302 being in...
-
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Epizyme, Transition Therapeutics
Tuesday, July 15, 2014 - 11:22am | 258Read More...In a note released Tuesday morning, H.C. Wainwright analyst Andrew Fein initiated a Buy on both Epizyme (NASDAQ: EPZM) and Transition Therapeutics (NASDAQ: TTHI) and set respective price targets of $40 and $10. Epizyme Amid the transition of big pharma from genetics to epigenetics, Fein likes...
-
Analyst Concerns On Vertex's Approved Drug
Wednesday, June 25, 2014 - 9:14am | 160Read More...HC Wainwright cut its rating on Vertex Pharmaceuticals (NASDAQ: VRTX) to Neutral after the stock rallied nearly 50 percent Tuesday. Analyst Andrew Fein started, “VRTX shares are finally appropriately valued.” Regarding VX-809’s commercialization, Fein shares his concerns:...
-
UPDATE: H.C. Wainwright Initiates Coverage on PharmAthene
Monday, March 10, 2014 - 4:12pm | 252Read More...In a report published Monday, H.C. Wainwright & Co. analyst Andrew Fein initiated coverage on PharmAthene (NYSE: PIP) with a Buy rating and $4.00 price target. Fein noted that shares represent an attractive point with “transformative” events over the next six months. The analyst wrote that the...
